Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SCP-CBD
- Development stage
- Preclinical
- Lead developer
- Nexus Alliance Biopharmaceuticals
- Modality
- Small Molecules
01
Overview
SCP-CBD is a preclinical small molecule candidate developed by Nexus Alliance Biopharmaceuticals, utilizing their proprietary Self-Correcting Polymer (SCP) technology to formulate cannabidiol (CBD). This formulation is designed to enhance the therapeutic profile of CBD, potentially improving its delivery, stability, and bioavailability for treating complex conditions. The candidate is currently being investigated for its potential in treating Ependymoma (a type of brain or spinal cord tumor), Meningitis carcinomatosis (the spread of cancer to the meninges), and Crohn's disease (a chronic inflammatory bowel disease). As a CBD-based therapy, its mechanism of action involves the modulation of the endocannabinoid system, including interactions with cannabinoid receptors and other non-cannabinoid targets like GPR55 and TRPV1, which play roles in inflammation and cell proliferation.
- Other names
- cannabidiolCBD
02
Targets
HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))CNR1 (Cannabinoid receptor 1)GPR55 (G protein-coupled receptor 55)TRPV1 (Transient receptor potential cation channel subfamily V member 1)
Beyond the preview
Go deeper on SCP-CBD.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SCP-CBD.